FMP
Eloxx Pharmaceuticals, Inc.
ELOX
OTC
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
0.0001 USD
3.0000000015651188e-12 (0.000003%)
ELOX Financial Statements
Year
2022
2021
2020
2019
Current Assets
20.13M
43.48M
25.89M
57.71M
Cash & Short Term Investments
19.21M
42.27M
24.67M
56.28M
Cash And Cash Equivalents
19.21M
42.27M
24.67M
22.49M
Short Term Investments
0
0
0
33.78M
Net Receivables
0
0
0
26k
Inventory
0
0
0
708k
Other Current Assets
829k
1.09M
1.05M
742k
Non-Current Assets
994k
1.66M
584k
1.24M
Property, Plant & Equipment
994k
1.66M
554k
1.13M
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
0
0
0
Tax Assets
0
0
0
0
Other Non-Current Assets
0
0
30k
113k
Other Assets
0
0
0
0
Total Assets
21.12M
45.14M
26.48M
58.95M
-
-
-
-
Current Liabilities
23.09M
9.96M
9.84M
11.81M
Accounts Payable
3.02M
1.38M
481k
1.87M
Short Term Debt
3.98M
0
5.24M
4.34M
Tax Payables
0
0
38k
43k
Deferred Revenue
12.54M
3.72M
805k
403k
Other Current Liabilities
45k
0
0
0
Total Current Liabilities
23.09M
9.96M
9.84M
11.81M
Total Non-Current Liabilities
8.69M
12.8M
6.41M
10.93M
Long-Term Debt
8.56M
12M
6.38M
10.5M
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
0
0
0
0
Total Liabilities
31.78M
22.75M
16.25M
22.73M
Other Liabilities
0
0
0
0
Stockholders Equity
-10.66M
22.38M
10.23M
36.21M
Common Stock
22k
22k
404k
402k
Retained Earnings
-274.39M
-238.32M
-171.6M
-137.02M
Accumulated Other Comprehensive Income/Loss
0
0
0
18k
Other Shareholders Equity
0
0
0
0
Total Liabilities and Stockholders Equity
21.12M
45.14M
26.48M
58.95M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-238.32M
-171.6M
-137.02M
-86.14M
Net Income
-36.06M
-66.73M
-34.58M
-50.87M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-274.39M
-238.32M
-171.6M
-137.02M
Other Distributions
-36.06M
-66.73M
-34.58M
-50.87M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
994k
1.66M
554k
1.13M
Annual Depreciation
695k
960k
571k
559k
Capital Expenditure
-66k
-89k
0
-40k
Net PPE
365k
788k
-17k
606k
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
